World's Premier Pharmaceutical Scientists Share Latest R&D Findings

November 02, 1998

Newest Drug Discoveries and Pharmaceutical Research to be Unveiled at
American Association of Pharmaceutical Scientists (AAPS)
Annual Meeting in San Francisco on November 15-19


Alexandria, VA -- November 2, 1998 -- Six thousand of the world's premier pharmaceutical researchers will gather in San Francisco on November 15-19 to discuss the latest scientific research and medical advances of 1998. A small sampling of the breakthroughs, presented for the first time at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, are listed below:

Sound-Alike Drugs Cause Potentially Dangerous Prescription Errors -- Nicoderm...Nitroderm; Xanax...Zantac: According to the FDA, look-alike and sound-alike drugs are causing roughly one death a day. Further, one out of every four reported prescription errors made by a pharmacist is due to name confusion. Pharmaceutical scientists are now studying this critical nomenclature issue and determining how to keep drugs with confusing names from reaching the market. Several of their recommendations to curb the probability of mistakes are currently being reviewed by the FDA.

Impact of High Altitude on Drug Efficacy -- Those who enjoy traveling to exotic locations, beware. The latest research shows that staying at high altitudes for more than 24 hours can alter the effect of drugs like Demerol, Lithium and even widely-used high altitude sickness medications like acetazolamide. How can skiers, hikers and tourists determine if their medication is ineffective at high altitudes? Pharmaceutical scientists are just beginning to study the topic and have some interesting research findings.

DHEA: Fountain of Youth or Dangerous Steroid? -- DHEA, developed to treat lupus, has recently made its way into mainstream health food stores and is being marketed as a naturally occurring "Fountain of Youth." The problem: The natural drug is converted to testosterone and can have unsightly, even dangerous side effects. The latest research shows that using DHEA can lead to facial hair growth, acne and osteoporosis in women or prostate cancer in men. After testing 16 mainstream DHEA products, researchers found that only half actually met manufacturers' label claims. Since the FDA does not yet monitor "dietary supplements," consumers need to be aware of the dangers of natural drugs.

No More Needles for Insulin Dependent Diabetes Sufferers? -- Millions of diabetes sufferers must receive daily insulin injections to avoid serious, often deadly complications. But there's hope: A leading Canadian scientist has developed and patented an oral insulin medication that's now set for human trials with the Health Protection Branch (the Canadian equivalent of the FDA). Next step -- approval in the US.

Key Seminars Topics Include:

Monday, November 16Tuesday, November 17Wednesday, November 18
AAPS is a professional, scientific society of more than 9,000 members employed in academia, industry, government and other research institutes worldwide. Founded in 1986, the goal of AAPS is to improve human health through the development of better pharmaceuticals. For more information about AAPS, visit our web site at www.aaps.org.
-end-
Editor's Note: To receive complete abstracts, available photos or to set up interviews with researchers, contact Ilisa Keith at 561-218-9990 or Lisa Mozloom lisa@zynyx.com at 305-672-4422.



American Association of Pharmaceutical Scientists

Related Drug Development Articles from Brightsurf:

FDA support for oncology drug development during COVID-19
This Viewpoint from the U.S. Food and Drug Administration puts into context recent guidance on clinical trials during COVID-19 for oncology and shares insight regarding regulatory challenges and lessons learned.

COVID-19 drug development could benefit from approach used against flu
A new study from researchers at The University of Texas at Austin has found that some antivirals are useful for more than helping sick people get better -- they also can prevent thousands of deaths and hundreds of thousands of virus cases if used in the early stages of infection.

Chemistry breakthrough could speed up drug development
Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development.

New model of the GI tract could speed drug development
MIT engineers have devised a way to speed new drug development by rapidly testing how well they are absorbed in the small intestine.

Super-charging drug development for COVID-19
Researchers are using cell-free manufacturing to ramp up production of valinomycin, a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures.

Drug development for rare diseases affecting children is increasing
The number of treatments for rare diseases affecting children has increased, a new study suggests.

New opportunity for cancer drug development
After years of research on cell surface receptors called Frizzleds, researchers at Karolinska Institutet in Sweden provide the proof-of-principle that these receptors are druggable by small molecules.

Novel paradigm in drug development
Targeted protein degradation (TPD) is a new paradigm in drug discovery that could lead to the development of new medicines to treat diseases such as cancer more effectively.

Turbo chip for drug development
In spite of increasing demand, the number of newly developed drugs decreased continuously in the past decades.

A breakthrough for brain tumor drug development
Glioblastoma is a devastating disease with poor survival stats due in part to a lack of preclinical models for new drug testing.

Read More: Drug Development News and Drug Development Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.